Viking Therapeutics's total assets for Q2 2025 were $827.85M, a decrease of -4.51% from the previous quarter. VKTX total liabilities were $32.39M for the fiscal quarter, a 61.34% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.